⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGM

SION

Sionna Therapeutics, Inc.

Healthcare · Biotechnology

7.48USD

+0.1800 (+2.47%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$-0.67▲$-0.734
Next quarter$-0.62▲$-0.7153
Current year$-2.56▼$-2.4145
Next year$-2.53▲$-2.7245

Recent quarters

Beat in 2 of the last 4

QuarterEstimateActualSurprise
2026-06-30$-0.65$-0.66-0.01 (-2.0%)
2026-03-31$-0.5$-0.6-0.10 (-19.1%)
2025-12-31$-0.54$-0.46+0.08 (+14.0%)
2025-09-30$-0.48$-0.46+0.01 (+3.2%)

Wall Street coverage

24 ratings from 10 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
GuggenheimDowngraded from BuyNeutral—Aug 11, 2026
WedbushDowngraded from OutperformNeutral$53 $5Aug 11, 2026
BTIGDowngraded from BuyNeutral—Aug 10, 2026
GuggenheimMaintainedBuy$50 $60Aug 7, 2026
CitizensReiteratedMarket Outperform$63May 26, 2026
Freedom BrokerDowngraded from BuyHold$38May 20, 2026
StifelMaintainedBuy$44 $55May 18, 2026
BTIGReiteratedBuy$58May 13, 2026
WedbushInitiatedOutperform$53May 5, 2026
Jones TradingMaintainedBuy$52 $63Apr 28, 2026
BTIGReiteratedBuy$58Apr 27, 2026
GuggenheimMaintainedBuy$45 $50Mar 3, 2026
BTIGReiteratedBuy$58Mar 2, 2026
CitizensInitiatedMarket Outperform$63Feb 24, 2026
BTIGReiteratedBuy$58Jan 14, 2026
BTIGMaintainedBuy$50 $58Jan 7, 2026
LifeSci CapitalInitiatedOutperform$60Dec 23, 2025
RBC CapitalDowngraded from Sector PerformUnderperform$24Dec 1, 2025
BTIGInitiatedBuy$50Nov 19, 2025
Freedom BrokerInitiatedBuy$38Oct 17, 2025
Jones TradingInitiatedBuy$46Sep 8, 2025
Raymond JamesInitiatedStrong Buy$45Sep 3, 2025
RBC CapitalInitiatedSector Perform$22Sep 3, 2025
StifelInitiatedBuy$32Mar 4, 2025

Insider transactions

58 filings from 10 insiders · 1 buy / 12 sell over 6m

Officers and directors of SION, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
THOMPSON PETER ADirectorSellindirect85.9k$44.86$3.85MJul 7, 2026
ORBIMED ADVISORS, L.L.C.UnknownSellindirect85.9k$44.86$3.85MJul 7, 2026
FITZPATRICK JENNIFER ROfficerExercise10.3k$6.11$63kJul 6, 2026
FITZPATRICK JENNIFER ROfficerSell10.3k$43.60$447kJul 6, 2026
THOMPSON PETER ADirectorSellindirect115.8k$45.50$5.27MJun 30, 2026
ORBIMED ADVISORS, L.L.C.DirectorSellindirect115.8k$45.50$5.27MJun 30, 2026
THOMPSON PETER ADirectorSellindirect101$44.49$4kMay 27, 2026
THOMPSON PETER ADirectorSellindirect293.0k$44.58$13.36MMay 11, 2026
ORBIMED ADVISORS, L.L.C.UnknownSellindirect293.0k$44.58$13.36MMay 11, 2026
THOMPSON PETER ADirectorSellindirect55.3k$44.52$2.47MApr 17, 2026
ORBIMED ADVISORS, L.L.C.UnknownSellindirect55.3k$44.52$2.47MApr 17, 2026
THOMPSON PETER ADirectorSellindirect510.6k$44.51$22.95MApr 16, 2026
ORBIMED ADVISORS, L.L.C.UnknownSellindirect510.6k$44.51$22.95MApr 16, 2026
FITZPATRICK JENNIFER ROfficerExercise10.3k$6.11$63kMar 5, 2026
FITZPATRICK JENNIFER ROfficerSell10.3k$33.86$347kMar 5, 2026
THOMPSON PETER ADirectorSellindirect31.0k$44.57$1.38MFeb 3, 2026
ORBIMED ADVISORS, L.L.C.DirectorSellindirect31.0k$44.57$1.38MFeb 3, 2026
TPG GP A, L.L.C.Beneficial Owner of more than 10% of a Class of SecuritySellindirect250.0k$40.00$10.00MJan 22, 2026
THOMPSON PETER ADirectorSellindirect33.4k$44.55$1.49MDec 24, 2025
ORBIMED ADVISORS, L.L.C.DirectorSellindirect33.4k$44.55$1.49MDec 24, 2025

Analyst Notes

Sign in to write

No analyst notes on SION yet.

Analyst Ratings

6 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current011000Hold2.91
1 mo ago18101Buy2.27
2 mo ago18101Buy2.27
Price target$15.17$5.00 – $63.00
+102.8% to target